Pharmapack will return to Paris in January 2026, with this year’s programme set to focus on pharmaceutical packaging challenges linked to the rapid growth of GLP-1 therapies and increasing sustainability requirements.

The event will take place at Paris Expo Porte de Versailles on January 21–22, 2026, marking the 25th edition of the conference and exhibition. Pharmapack is expected to bring together more than 6,000 attendees from 90 countries, alongside 400 exhibitors and 80 speakers from across the pharmaceutical packaging, drug delivery and medical device sectors.

The 2026 agenda will explore how packaging and delivery technologies are evolving in response to two major industry pressures: rising demand for injectable GLP-1 medicines and regulatory expectations around environmental performance. Sessions will examine topics including eco-design, material innovation, digitalisation of connected devices and manufacturing considerations linked to large-scale biologics delivery.

Sherma Ellis-Daal, brand director for Pharmapack, said the role of packaging is increasingly central to pharmaceutical strategy.

“Pharmaceutical packaging and delivery systems are no longer just operational concerns, they are strategic levers for patient experience and market access,” Ellis-Daal said. “Pharmapack brings together the people and insights needed to solve real-world challenges and future-proof the supply chain.”

The conference programme will include discussions on geopolitical pressures affecting packaging supply chains, with a transatlantic debate examining differences in regulatory and manufacturing approaches between the USA and Europe. Other sessions will focus on applying eco-design principles without compromising product protection or compliance, drawing lessons from both pharmaceutical and cosmetics sectors.

Artificial intelligence will also feature in the agenda, with sessions examining how AI tools are being applied to regulatory intelligence, real-time data analysis and pharmacovigilance, alongside discussion of implementation challenges and governance requirements.

In addition, the programme will address the growing role of connected care devices, including how pharmaceutical companies are approaching wearable technologies and digital tools for chronic disease management.

Pharmapack 2026 will be supported by six premium partners: Aptar, Gerresheimer, SCHOTT Pharma, Stevanato Group, West and BD. The companies will participate across exhibition, content and networking activities during the event.

The Pharmapack Awards, which recognise innovation in pharmaceutical packaging, sustainability and patient-centred design, will be sponsored by AAE B.V. for the 2026 edition.